Mohamed Amine Guerroudji | Brain cancer | Best Researcher Award

Posted on by sciencefather

Mr. Mohamed Amine Guerroudji | Brain cancer | Best Researcher Award

Research Scholar|CENTER FOR DEVELOPMENT OF ADVANCED TECHNOLOGIES (CDTA), Algeria

ohamed Amine Guerroudji, né le 29 mai 1987 à Blida, Algérie, est un docteur en électronique spécialisé dans le traitement d’images médicales, en particulier la détection automatisée des micro-calcifications dans les mammographies. Il exerce depuis 2015 en tant que professeur de mathématiques au cycle moyen et a assuré plusieurs missions d’enseignement vacataire à l’Université de Blida, dans les domaines de la programmation en C, du MATLAB, des méthodes numériques, et de l’électronique générale. Passionné par la recherche appliquée, il a publié dans des conférences et revues internationales, notamment sur l’amélioration du contraste et la segmentation des images médicales. Il est également membre actif des comités scientifiques de conférences internationales en photonique et optique. Polyglotte (arabe, français, anglais), il combine rigueur scientifique, esprit d’équipe et adaptabilité dans ses missions pédagogiques et de recherche.

Profile

🎓 Education

Mohamed Amine Guerroudji a obtenu son doctorat en électronique en avril 2017 à l’Université Mouloud Mammeri de Tizi-Ouzou avec mention très honorable, avec une recherche axée sur la segmentation des images mammographiques pour détecter les micro-calcifications. Il détient un Master en électronique (traitement de l’information et systèmes électroniques) obtenu en 2013 à l’Université Saad Dahlab de Blida, avec un mémoire en imagerie médicale noté Très Bien. Sa licence en génie électronique (option réseaux et télécommunications) a été obtenue en 2011 à la même université. Il est également titulaire d’un baccalauréat technique en fabrication mécanique (2007), d’une formation en premiers secours (Croissant Rouge Algérien, 2010), et a suivi une formation sur l’usage des bases de données scientifiques (Web of Science, 2014). Son parcours académique illustre un engagement profond envers l’innovation technologique et la recherche appliquée en électronique médicale.

🧪 Experience

Depuis 2015, Mohamed Amine Guerroudji enseigne les mathématiques au cycle moyen en Algérie. Parallèlement, il a été enseignant vacataire à l’Université de Blida entre 2013 et 2018, intervenant dans des modules tels que TP Langage C, TP Méthodes Numériques, TP MATLAB, Outils de Programmation Mathématique et Électronique générale. Il a également dispensé des cours d’électricité générale et d’électronique dans un institut spécialisé en arts graphiques. Son expérience diversifiée dans l’enseignement supérieur et secondaire reflète sa capacité à s’adapter à différents publics et niveaux d’apprentissage. Il combine son savoir technique avec une approche pédagogique pratique, en mettant l’accent sur la programmation appliquée et la modélisation mathématique. Son expertise couvre également l’utilisation de logiciels comme MATLAB, Workbench, VHDL et C++, renforçant sa polyvalence dans le domaine de l’électronique appliquée.

🏅 Awards and Honors

Mohamed Amine Guerroudji a reçu plusieurs distinctions académiques, notamment la mention Très Honorable pour sa thèse de doctorat en électronique en 2017 et la mention Très Bien pour son mémoire de master en imagerie médicale. Il est reconnu au niveau international pour ses contributions scientifiques dans le domaine du traitement d’images médicales, avec des publications dans des conférences de renom telles que ISPA 2017, ICESTI 2016 et des revues comme Optik – International Journal for Light and Electron Optics. Il a également été sélectionné comme membre du comité scientifique de conférences prestigieuses sur l’optique et la photonique : OPAL 2018 (Barcelone) et OPAL 2019 (Amsterdam). Ces reconnaissances soulignent la qualité et l’impact de ses travaux de recherche, ainsi que son implication dans la communauté scientifique internationale.

🔬 Research Focus

Mohamed Amine Guerroudji concentre sa recherche sur le traitement d’images médicales, plus précisément sur la détection automatique des micro-calcifications mammaires à partir de clichés mammographiques. Son travail de doctorat portait sur la segmentation d’images pour l’aide au diagnostic précoce du cancer du sein, en utilisant des algorithmes comme les contours actifs (géometric deformable models), les transformations morphologiques (white Top-Hat) et la méthode de seuillage d’Otsu. Il a proposé de nouvelles approches d’amélioration de contraste dans les mammographies, visant à rendre les foyers pathologiques plus visibles pour les praticiens. Ses recherches intègrent des techniques avancées de traitement numérique, associant la programmation MATLAB à l’analyse morphométrique. À travers ses publications, il cherche à améliorer la précision et l’automatisation dans les systèmes d’aide à la décision médicale, tout en explorant l’intersection entre l’électronique, la médecine et l’intelligence artificielle.

✅ Conclusion

Mohamed Amine Guerroudji est un expert algérien en électronique et traitement d’images médicales, combinant expérience pédagogique, excellence académique et innovation scientifique au service de la santé et de l’éducation.

Publications

Pedram Fadavi | Radiation oncology | Best Researcher Award

Posted on by sciencefather

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡

Profile

Education 🎓

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖

Experience 👨‍🏫

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬

Research Interests 🔬

Dr. Fadavi’s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. 💻🧬Awards & Recognitions 🏅

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅

Publications 📚

Natalia Baran | Cancer Research | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Natalia Baran | Cancer Research | Best Researcher Award

Leading Attending at InselSpital Bern, Switzerland.

Dr. Natalia Baran is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, where she focuses on developing novel therapeutic strategies targeting metabolic vulnerabilities in leukemia. Her expertise lies in understanding how metabolic reprogramming can lead to drug resistance and contribute to leukemia progression. With a medical background and extensive experience in both clinical and research settings, Dr. Baran has been at the forefront of studies that aim to modulate metabolic pathways to enhance anti-leukemic responses. By combining insights from molecular biology, immunology, and clinical practice, she is actively working toward discovering innovative treatments for leukemia. Dr. Baran’s research holds great promise in advancing leukemia therapy, particularly by targeting metabolic reprogramming in the context of therapy resistance. Her multidisciplinary approach, integrating clinical data with laboratory research, makes her a key figure in leukemia research.

Profile

Scopus

Google Scholar

Orcid

Education:

Dr. Natalia Baran completed her undergraduate studies in Biotechnology, earning a Master of Science degree in 2006 from Wroclaw University of Science and Technology in Poland. She further pursued medical education and obtained her Medical Doctor (MD) degree from Wroclaw Medical University in 2007. Driven by her passion for research, Dr. Baran earned a Ph.D. in Medicine from the University of Bonn in 2015. Her doctoral research laid the foundation for her current focus on leukemia and metabolic reprogramming. In addition, Dr. Baran underwent extensive postdoctoral training at MD Anderson Cancer Center, where she honed her expertise in hematology and oncology, contributing significantly to translational research in leukemia. Her diverse educational background, blending science and medicine, has shaped her comprehensive approach to cancer research.

Professional Experience:

Dr. Baran has a rich professional experience that bridges clinical practice and cutting-edge research. After completing her MD, she pursued clinical residencies in Internal Medicine, Hematology, and Oncology at prestigious German institutions, including the University of Heidelberg and the University of Bonn. This clinical experience laid the groundwork for her subsequent focus on leukemia research. In 2016, she joined MD Anderson Cancer Center as a Postdoctoral Fellow in the Department of Leukemia. During her postdoctoral tenure, Dr. Baran worked closely with Dr. Marina Konopleva, exploring the role of metabolic pathways in leukemia resistance. By 2022, she had transitioned to an Assistant Professor role, continuing her translational research in leukemia, with a particular emphasis on identifying novel therapeutic strategies. Her clinical and research experiences synergize to enhance her contributions to the leukemia research community.

Research Interests:

Dr. Baran’s research is primarily centered on exploring metabolic vulnerabilities and their role in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Her work seeks to understand the mechanisms through which metabolic reprogramming in leukemia cells contributes to drug resistance and tumor progression. Dr. Baran is particularly interested in how modulating the metabolic environment can enhance the effectiveness of leukemia therapies. By focusing on the interplay between metabolism and leukemic cell survival, she aims to identify new therapeutic strategies that target metabolic pathways to overcome resistance to traditional treatments. Her research also explores how immune modulation can be integrated with metabolic interventions to develop more efficient leukemia therapies.

Awards and Honors:

Dr. Baran has received recognition for her contributions to leukemia research, although specific awards are not detailed in available sources. However, her research has been featured prominently in major scientific forums, including the Annual Metabolism in Cancer Symposium organized by MD Anderson. Her work has earned her respect within the scientific community, as evidenced by her continued role as an Assistant Professor and her involvement in prestigious cancer research initiatives. Dr. Baran’s impact is evident in her ongoing efforts to bridge the gap between basic science and clinical application, aiming to revolutionize leukemia treatment.

Skills:

Dr. Baran’s research skills encompass a wide range of techniques in molecular biology, cell culture, and metabolic analysis. She is highly proficient in studying the metabolic pathways that drive leukemia, using state-of-the-art technologies such as high-resolution metabolic flux analysis, RNA sequencing, and advanced cell imaging. Dr. Baran is skilled at integrating basic science with clinical data, ensuring that her research translates into practical therapeutic interventions. Her expertise in immunology further complements her research in leukemia, allowing her to investigate the potential of combining metabolic therapies with immune modulation to improve patient outcomes. Her interdisciplinary approach is a key strength in her ongoing work in leukemia research.

Publication Top Notes

A Selective BCL-XL PROTAC Degrader Achieves Safe and Potent Antitumor Activity

  • Authors: S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, et al.
  • Journal: Nature Medicine
  • Volume: 25(12), Pages 1938–1947
  • Cited by: 515
  • Year: 2019

Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells

  • Authors: M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, et al.
  • Journal: Blood, The Journal of the American Society of Hematology
  • Volume: 137(5), Pages 624–636
  • Cited by: 226
  • Year: 2021

Inhibiting Glutaminase in Acute Myeloid Leukemia: Metabolic Dependency of Selected AML Subtypes

  • Authors: P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, et al.
  • Journal: Oncotarget
  • Volume: 7(48), Pages 79722
  • Cited by: 194
  • Year: 2016

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials

  • Authors: TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, et al.
  • Journal: Nature Medicine
  • Volume: 29(1), Pages 115–126
  • Cited by: 182
  • Year: 2023

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  • Authors: N Baran, M Konopleva
  • Journal: Clinical Cancer Research
  • Volume: 23(10), Pages 2382–2390
  • Cited by: 126
  • Year: 2017

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-Like Responses Against CD30+ Malignancies

  • Authors: LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, et al.
  • Journal: Clinical Cancer Research
  • Volume: 27(13), Pages 3744–3756
  • Cited by: 117
  • Year: 2021

Clonal Selection and Therapy Resistance in Acute Leukemias: Mathematical Modelling Explains Different Proliferation Patterns at Diagnosis and Relapse

  • Authors: T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
  • Journal: Journal of The Royal Society Interface
  • Volume: 11(94), Article ID 20140079
  • Cited by: 106
  • Year: 2014

Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia

  • Authors: Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, et al.
  • Journal: Signal Transduction and Targeted Therapy
  • Volume: 7(1), Article ID 51
  • Cited by: 104
  • Year: 2022

Conclusion:

Dr. Natalia Baran is a prominent researcher whose work in leukemia has the potential to transform therapeutic approaches, especially through targeting metabolic pathways. Her strong academic background, combined with extensive clinical and research experience, enables her to address one of the most pressing challenges in leukemia treatment: drug resistance. By focusing on metabolic reprogramming, Dr. Baran is paving the way for innovative strategies to combat leukemia and improve patient outcomes. Her expertise in integrating basic research with clinical applications ensures that her contributions will have a lasting impact on the field of oncology, particularly in the development of new, more effective therapies for leukemia.